NCT03647670 - A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

October 16, 2018

Study Completion Date

October 16, 2018

Conditions

Phase 1

Interventions

DRUG

PF-04965842

orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.

DRUG

Midazolam

substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels